Clinical Ophthalmology (Feb 2024)
Latanoprostene Bunod 0.024% in Patients with Open-Angle Glaucoma Switched from Prior Pharmacotherapy: A Retrospective Chart Review
Abstract
Constance O Okeke,1 Nora Lee Cothran,2 Desirae A Brinkley,3 Kamran Rahmatnejad,4 Frank J Rodiño,5 James E Deom6 1Virginia Eye Consultants/CVP, Norfolk, VA, USA; 2The Eye Institute of West Florida, Largo, FL, USA; 3Eye Specialty Group, Memphis, TN, USA; 4Eastern Virginia Medical School, Norfolk, VA, USA; 5Churchill Outcomes Research, Red Bank, NJ, USA; 6Hazleton Eye Specialists, Hazle Township, PA, USACorrespondence: Constance O Okeke, Virginia Eye Consultants/CVP, 241 Corporate Blvd, Norfolk, VA, 23320, USA, Tel +1 757-622-2200, Fax +1 757-622-4866, Email [email protected]: Latanoprostene bunod 0.024% (LBN, Vyzulta®) is a nitric oxide-donating prostaglandin analog (PGA). We investigated the real-world efficacy and safety of LBN in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT) who switched their existing intraocular pressure (IOP)-lowering treatment(s) to LBN.Methods: This non-interventional, multicenter (United States), retrospective chart review included patients aged ≥ 18 years with OHT and/or mild-to-moderate OAG diagnoses taking 1– 2 IOP-lowering treatments at the time of switch to LBN (index visit). Chart-extracted data included demographics, diagnoses, IOP and ocular assessments, other IOP-lowering treatments, adverse events (AEs), and reasons for discontinuation. The main study outcome was IOP change from the index visit to each of the next 2 chart-recorded follow-up visits. Analysis groups included the overall dataset and 2 subgroups of patients switched from PGA therapy to LBN: “PGA-all” subgroup [all patients previously on a PGA with/without another IOP-lowering product] and “PGA-monotherapy” subgroup [patients previously on a PGA alone]). Additional ocular outcomes (eg, visual acuity) were examined, if available.Results: The overall dataset included 49 patients (46 had OAD alone, 2 had OHT alone, and 1 had both). The PGA-all subgroup and PGA-monotherapy subgroups had 41 and 32 patients, respectively. Switching to LBN led to a ~25% IOP reduction from the index visit to Visit 1 that was sustained at Visit 2. IOP findings in the PGA-all and PGA-monotherapy subgroups were consistent with the overall dataset. No meaningful changes in other ocular outcomes were found. Of 14 ocular AEs, 3 were recorded as such (mild in severity, considered unrelated to treatment), and 11 were identified through review of interval ocular histories (no severity/relatedness information); none led to discontinuation.Conclusion: In this short-term retrospective chart review of mild-to-moderate OAG/OHT, switching prior IOP-lowering therapy to LBN produced an additional ~25% IOP reduction and appeared to be well tolerated.Keywords: latanoprostene bunod, LBN, prostaglandin analog, PGA, ocular hypertension, OHT, open-angle glaucoma, OAG, intraocular pressure, IOP
